sdü tıp fak derg Medical Journal of Süleyman Demirel University 2602-2109 Süleyman Demirel Üniversitesi 10.17343/sdutfd.1297128 Clinical Sciences Klinik Tıp Bilimleri COVİD 19’UN KANSER HASTALARINDA YOĞUN BAKIM MORTALİTESİ ÜZERİNE ETKİSİ THE IMPACT OF COVID-19 ON MORTALITY IN CANCER PATIENTS IN THE INTENSIVE CARE UNIT https://orcid.org/0000-0002-6210-5962 Karabacak Pınar SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0002-1971-6856 Bindal Ahmet SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0002-8070-0159 Özden Eyyüp Sabri SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0003-0385-2308 Özcan Mustafa Soner SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0002-8622-6072 Osmanlıoğlu Hacı Ömer SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ https://orcid.org/0000-0001-7784-1818 Kırdemir Pakize SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ 09 23 2023 30 3 396 403 05 15 2023 08 10 2023 Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 1994 Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

AmaçYeni koronavirüs hastalığı (COVİD 19) Aralık 2019 yılındaortaya çıkan mortalitesi yüksek bir solunum sistemihastalığıdır. Kalp hastalığı, hipertansiyon, diyabetve kronik obstrüktif akciğer hastalığı olan ve bağışıklıksistemi zayıflamış kişiler, ciddi komplikasyonlar açısındandaha yüksek risk altındadır. Kanser hastaları hemhastalığın hem de tedavilerinin getirdiği etkiler nedeniylepandemi sürecinden olumsuz etkilendi. Bu çalışmadaamacımız COVİD 19’ un yoğun bakımda takipedilen kanser hastalarındaki mortalite üzerine etkisinindeğerlendirilmesidir.Gereç ve YöntemOcak 2020- Nisan 2022 yılları arasında yoğun bakımdatakip edilen 275 COVİD 19 hastası retrospektifolarak incelendi. Bu hasta grubunda kanser tanısımevcut 72 hasta tespit edildi. Hastalar; grup 1 kanseriolmayan hastalar(n=203), grup 2 kanseri olan hastalar(n=72) olarak iki gruba ayrıldı. Tüm hastaların yaş,cinsiyet, ek hastalık, PCR test pozitiflikleri, laboratuvarparametreleri, APACHE II, SOFA skorları, yoğun bakımkalış süresi, mekanik ventilatör gereksinimi, mekanikventilatör süreleri kaydedildi.BulgularHipertansiyon Grup 1 de Grup 2 ye kıyasla anlamlıolarak daha yüksekti [(sırayla 97 (%48) ve 24 (%33);p

ObjectiveNew corona virus disease (COVID-19) is a respiratorydisease associated with high mortality that emergedin December 2019. Individuals with preexisting healthconditions, such as heart disease, hypertension,diabetes, and chronic obstructive pulmonary disease,and those with weakened immune systems are atincreased risk for severe complications. Cancerpatients have been adversely affected by the pandemic,both due to the disease itself and its treatments. Theaim of this study is to evaluate the impact of COVID 19on mortality in cancer patients followed in the intensivecare unit (ICU).Material and MethodWe conducted a retrospective analysis of 275COVID-19 patients who were admitted to the ICUbetween January 2020 and April 2022. Among thesepatients, 72 had a cancer diagnosis and were classifiedinto two groups: Group 1 (n=203) included patientswithout cancer, and Group 2 (n=72) included patientswith cancer. We recorded age, gender, comorbidities,PCR test results, laboratory parameters, APACHE2and SOFA scores, duration of ICU stay, mechanicalventilation requirement, and duration of mechanicalventilation for all patients.ResultsHypertension was significantly more common in Group1 compared to Group 2 [97 (48%) and 24 (33%),respectively); p

 Covid 19 Cancer Comorbidity Critical Care Covid 19 Kanser Komorbidite Yoğun Bakım 1. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z et al. Epidemiological, comorbidity factors with severity and prognosis of COVID- 19: a systematic review and meta-analysis. Aging. 2020 Jul 13;12(13):12493-12503. doi: 10.18632/aging.103579. 2. Zaoui N, Bachir N, Terki A, Boukabous A. Myocardite à COVID- 19 : « à propos d'une série monocentrique de 33 cas » [COVID-19 myocarditis : "About a monocentric series of 33 cases"]. Ann Cardiol Angeiol. 2022 Oct;71(4):219-222. French. doi: 10.1016/j.ancard.2022.08.004. 3. Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust. 2020 Jul;213(2):54- 56.e1. doi: 10.5694/mja2.50674. 4. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. 5. Han X, Ye Q. Kidney involvement in COVID-19 and its treatments. J Med Virol. 2021 Mar;93(3):1387-1395. doi: 10.1002/jmv.26653. 6. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020 Dec;13(12):1833-1839. doi: 10.1016/j.jiph.2020.07.014. 7. Sidaway P. COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol. 2020 Jun;17(6):336. doi: 10.1038/s41571-020- 0366-2. 8. Rucinska M, Nawrocki S. COVID-19 Pandemic: Impact on Cancer Patients. Int J Environ Res Public Health. 2022 Sep 30;19(19):12470. doi: 10.3390/ijerph191912470. 9. Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E et al. Evaluation of COVID-19 impact on DELAYing diagnostic- therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open. 2022 Apr;7(2):100406. doi: 10.1016/j.esmoop.2022.100406. 10. İlgün AS, Özmen V. The Impact of the COVID-19 Pandemic on Breast Cancer Patients. Eur J Breast Health. 2021 Dec 30;18(1):85-90. doi: 10.4274/ejbh.galenos.2021.2021-11-5. 11. Moiseev S, Avdeev S, Brovko M, Akulkina L, Fomin V. Cancer in intensive care unit patients with COVID-19. J Infect. 2020 Aug;81(2):e124-e125. doi: 10.1016/j.jinf.2020.05.053. 12. Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1431-1437. doi: 10.1016/j.dsx.2020.07.037. 13. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020 Aug 15;17(3):519-527. doi: 10.20892/j. issn.2095-3941.2020.0289. 14. Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/ S1470-2045(20)30096-6. 15. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 Jul;31(7):894-901. doi: 10.1016/j.annonc. 2020.03.296. 16. Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol. 2021 May;26(5):826-834. doi: 10.1007/s10147-021-01863-6. 17. Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM et al. Platelet- to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020 Sep;92(9):1533- 1541. doi: 10.1002/jmv.25767. 18. Yeoh CB, Lee KJ, Rieth EF, Mapes R, Tchoudovskaia AV, Fischer GW et al. COVID-19 in the Cancer Patient. Anesth Analg. 2020 Jul;131(1):16-23. doi: 10.1213/ ANE.0000000000004884. 19. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020 Jun;10(6):783-791. doi: 10.1158/2159-8290.CD-20-0422. 20. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020 Oct;92(10):2067-2073. doi: 10.1002/jmv.25972. 21. Lin YC, Tsai YH, Huang CC, Hsu KH, Wang SW, Tsao TC et al. Outcome of lung cancer patients with acute respiratory failure requiring mechanical ventilation. Respir Med. 2004 Jan;98(1):43-51. doi: 10.1016/j.rmed.2003.07.009. 22. Englum BR, Prasad NK, Lake RE, Mayorga-Carlin M, Turner DJ, Siddiqui T et al. Impact of the COVID-19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System. Cancer. 2022 Mar 1;128(5):1048-1056. doi: 10.1002/cncr.34011. 23. Kuzuu K, Misawa N, Ashikari K, Kessoku T, Kato S, Hosono K et al. Gastrointestinal Cancer Stage at Diagnosis Before and During the COVID-19 Pandemic in Japan. JAMA Netw Open. 2021 Sep 1;4(9):e2126334. doi: 10.1001/jamanetworkopen. 2021.26334. 24. Burki TK. Cancer care in the time of COVID-19. Lancet Oncol. 2020 May;21(5):628. doi: 10.1016/S1470-2045(20)30201-1. 25. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 Jun;32(6):787-800. doi: 10.1016/j.annonc. 2021.02.024. 26. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-941. doi: 10.1158/2159-8290.CD-20-0516. 27. Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M et al. Cancer and COVID-19: analysis of patient outcomes. Future Oncol. 2021 Sep;17(26):3499-3510. doi: 10.2217/fon- 2021-0121. 28. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9. Epub 2020 May 28. Erratum in: Lancet. 2020 Sep 12;396(10253):758.